| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1038256282 |
| P356 | DOI | 10.2165/00019053-200523090-00006 |
| P698 | PubMed publication ID | 16153136 |
| P50 | author | Greg L Plosker | Q62563006 |
| David P Figgitt | Q62563786 | ||
| P2860 | cites work | The comparative efficacy and safety of teicoplanin and vancomycin | Q39601973 |
| Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections | Q42168290 | ||
| Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial | Q42603615 | ||
| Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial | Q43546278 | ||
| Linezolid resistance in a clinical isolate of Staphylococcus aureus | Q43690311 | ||
| Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin | Q43773396 | ||
| Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia | Q43781411 | ||
| Economic impact and formulary positioning of linezolid: a new anti-Gram-positive antimicrobial | Q43942328 | ||
| Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. | Q43990373 | ||
| Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections | Q43996924 | ||
| Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. | Q44019739 | ||
| Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy | Q44068547 | ||
| Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000) | Q44429058 | ||
| Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial | Q44439560 | ||
| Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals | Q44502785 | ||
| Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia | Q44647040 | ||
| Early Switch and Early Discharge Opportunities in Intravenous Vancomycin Treatment of Suspected Methicillin-Resistant Staphylococcal Species Infections | Q44652724 | ||
| Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin | Q44715393 | ||
| Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. | Q44719260 | ||
| Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin | Q44721295 | ||
| Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections | Q44732971 | ||
| Daptomycin | Q44768109 | ||
| An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects | Q44841752 | ||
| Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia | Q44931177 | ||
| Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses | Q44975087 | ||
| Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus | Q45044145 | ||
| Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus | Q46429720 | ||
| Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain | Q46514194 | ||
| Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. | Q51671442 | ||
| Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database | Q57238054 | ||
| Hospital response to DRG refinements: the impact of multiple reimbursement incentives on inpatient length of stay | Q73912602 | ||
| Nosocomial pneumonia: a cost-of-illness analysis | Q74128213 | ||
| Does prospective payment reduce inpatient length of stay? | Q74449119 | ||
| Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? | Q77965660 | ||
| Linezolid: an oxazolidinone antimicrobial agent | Q78721705 | ||
| Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 | ||
| Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study | Q31918107 | ||
| Linezolid: a review of its use in the management of serious gram-positive infections | Q33337060 | ||
| Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections | Q33836490 | ||
| Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group | Q33852247 | ||
| Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study | Q33973732 | ||
| Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections | Q33981016 | ||
| Staphylococcus aureus resistant to vancomycin--United States, 2002. | Q34141070 | ||
| Linezolid: the first oxazolidinone antimicrobial | Q34170643 | ||
| Methicillin resistant Staphylococcus aureus in the critically ill. | Q34282406 | ||
| Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate | Q34284305 | ||
| Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model | Q34583266 | ||
| Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit | Q34769024 | ||
| Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies | Q35013856 | ||
| Linezolid: in infants and children with severe Gram-positive infections | Q35135386 | ||
| A practical guide to the treatment of complicated skin and soft tissue infections | Q35166376 | ||
| A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients. | Q35620918 | ||
| Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species | Q35641652 | ||
| Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens | Q35701450 | ||
| Healthcare-associated pneumonia in adults: management principles to improve outcomes | Q35957940 | ||
| The economic impact of Staphylococcus aureus infection in New York City hospitals | Q37064347 | ||
| P433 | issue | 9 | |
| P921 | main subject | linezolid | Q411377 |
| gram-positive bacteria | Q857288 | ||
| P304 | page(s) | 945-964 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections | |
| P478 | volume | 23 |
| Q38202581 | Antimicrobial agents, drug adverse reactions and interactions, and cancer |
| Q38068456 | Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections |
| Q36930855 | Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature |
| Q33658487 | Estimating the potential annual welfare impact of innovative drugs in use in Switzerland |
| Q37600395 | Health economic issues in the treatment of drug-resistant serious Gram-positive infections |
| Q34894133 | Linezolid for the treatment of drug-resistant infections |
| Q91831719 | Linezolid for the treatment of postneurosurgical infection caused by methicillin-resistant Staphylococcus |
| Q42745595 | Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment |
| Q36967288 | Linezolid: effectiveness and safety for approved and off-label indications |
| Q92154684 | Management of methicillin-resistant Staphylococcus aureus mediated ventilator-associated pneumonia |
| Q36735202 | Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. |
| Q33736523 | Revisiting Methicillin-Resistant Staphylococcus aureus Infections |
| Q40577600 | Sequential antimicrobial treatment with linezolid for neurosurgical infections: efficacy, safety and cost study |
| Q24234764 | Teicoplanin versus vancomycin for proven or suspected infection |
| Q51505589 | Use of linezolid in neonatal and pediatric inpatient facilities--results of a retrospective multicenter survey. |
| Q46847070 | Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients |
Search more.